Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01984359 · ClinicalTrials.gov registry record · NA
HPV Serum DNA Levels Predicting Outcome in p16+ Squamous Cell Head and Neck Cancer
A NA study, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- NA
- Development phase
- 80
- Enrollment target
NCT01984359 is a NA study that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 80 participants.
The verdict
NCT01984359, a NA study, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- NA
- Development phase
- 80 participants
- Enrollment target
Study Summary
To assess in an exploratory manner, the pronostic utility for locoregional control, progression-free and distant metastasis-free survival of a pre-therapy and post-therapy blood DNA test of HPV E6 and E7 DNA for subtypes 16 and 18 in p16+ and/or HPV+ oropharyngeal cancer patients. This will entail analysis of both initial pre-therapy HPV level as a continuous variable and initial post-therapy HPV level as a dichotomous variable.
Interventions
- OTHER Obtaining Human tissue
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2013-05 |
| Est. Completion | 2018-05-24 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01984359
The ClinicalTrials.gov registry entry for NCT01984359 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Obtaining Human tissue is the first listed.
NCT01984359 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01984359 about?
NCT01984359 is a clinical study titled "HPV Serum DNA Levels Predicting Outcome in p16+ Squamous Cell Head and Neck Cancer". To assess in an exploratory manner, the pronostic utility for locoregional control, progression-free and distant metastasis-free survival of a pre-therapy and post-therapy blood DNA test of HPV E6 and E7 DNA for subtypes 16 and 18 in p16+ and/or HPV+ oropharyngeal cancer patients. This will entail a...
What is the current status of trial NCT01984359?
This trial is currently completed. It is a NA study. The enrollment target is 80 participants. The study started on 2013-05. Estimated completion is 2018-05-24.
What interventions are being tested in trial NCT01984359?
The interventions under investigation include: Obtaining Human tissue (OTHER).
Who is sponsoring clinical trial NCT01984359?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.